Gilead Sciences to Acquire Cancer Treatment Developer Tubulis For Up To $5 Billion

 Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

– Acquisition Adds TUB-040, a NaPi2b Targeting ADC for Ovarian Cancer and other Solid Tumors, to Gilead Pipeline –

– Industry Leading ADC Platform That Includes its Clinically-Validated Tubutecan Linker-Payload Technology and Next-Generation Platform to Expand Gilead’s ADC Capabilities –

https://www.businesswire.com/news/home/20260406252364/en/Gilead-to-Acquire-Tubulis-Adding-Potentially-Best-in-Class-Antibody-Drug-Conjugate-and-Next-Generation-Platform-to-Further-Strengthen-Oncology-Pipeline